EVALUATION OF THE EFFECT OF THE CARDIOPROTECTOR TRIMETAZIDINE ON THE CLINICAL COURSE OF MYOCARDIAL INFARCTION COMPLICATED BY CHRONIC HEART FAILURE IN YOUNG PATIENTS
Keywords:
myocardial infarction, chronic heart failure, young age, trimetatisine, 6-minute walking test, ECG, EchoCG, etcAbstract
In this scientific work, data were analyzed on the effect of the cardioprotector trimetazidine on the clinical course of myocardial infarction of complicated chronic heart failure (CHF) in young patients. The study included 63 patients (36 men, 27 women) with myocardial infarction with CHF according to NYHA I–III FC, aged 18 to 44 years (average age 36.0±7.8 years). All patients underwent anamnesis collection, anthropometry, general clinical examination with an assessment of the symptoms of CHF on the SHOKS scale, and an assessment of exercise tolerance was carried out using a 6-minute walking test and a bendpnea test. Instrumental studies such as ECG, Holter ECG, EchoCG, UTT were also performed using a standard technique. All patients, depending on the treatment methods, were divided into 2 groups. The first group included 34 patients [men – 22 (64,7%), women – 12 (35.3%)] who, along with basic therapy, received the drug trimetazidine (preduktal OD, Gedeon Richter, Hungary) at a dose of 80 mg 1 time per day for 3 months. The second group (control group) included 29 patients [men – 14 (48%), women - 15 (52%)] who received standard therapy (beta-blockers, ACE inhibitors, calcium antagonists, nitrates, diuretics, etc.). Trimetazidine is a high-class cardioprotector, which, against the background of long-term use (from 3 to 6 months), improves the metabolism of the heart muscle and is indicated for all patients with coronary heart disease who have suffered a myocardial infarction in the early stages of CHF development.
References
Akatova U.V. "Trimetazidine (review of recent foreign publications)." Consilium Medicum 20.10 (2018): 53-58. (in Russ).
2. Aronov, D. M., et al. "The agreed opinion of experts on the expediency of using the myocardial cytoprotector trimetazidine (Preductal MV) in the complex therapy of patients with chronic forms of coronary heart disease." Atmosphere. Cardiology News 3 (2012): 42-44. (in Russ).
Askarov, I.K. et al. "Predictors of Cardioprotection in Patients with Chronic Heart Failure as A Consequence of Myocardial Infarction." Periodica Journal of Modern Philosophy, Social Sciences and Humanities 17 (2023):137-140. (in Russ).
Zhitnikova, L.M. "Trimetazidine in the metabolic therapy of cardiovascular diseases." Breast cancer 20.14 (2012): 718-723. (in Russ).
Kartashova, E.A. Comparative evaluation of the efficacy and safety of trimetazidine and mildronate in the complex therapy of coronary heart disease. Diss. Dissertation for the degree of Candidate of Medical Sciences/Rostov State Medical University. Rostov-on-Don, 2009 (in Russ).
Kremneva, L. V. Et al. "Trimetazidine: mechanism of action and results of controlled studies in patients with coronary heart disease." Cardiovascular therapy and prevention 4.2 (2005): 99-107. (in Russ).
Rizaev J.A. et al. "Current trends in the prevalence and outcome of cardiovascular diseases among the population of the Republic of Uzbekistan." Journal of cardiorespiratory research 1.1 (2023): 18-23. (in Russ).
Khasanjanova F.O. et al. "Features Of The Clinical Course Of Myocardial Infarction With Chronic Heart Failure In Young Patients." Central Asian Journal of Medical and Natural Science 4.2 (2023): 637-640. (in Russ).
Khasanjanova F.O. et al. "Differences in the incidence of major complications in patients with acute myocardial infarction." Current scientific research in the modern world 10-6 (2018): 39-41. (in Russ).
Khasanjanova F.O. et al. "Clinical features and incidence of myocardial infarction in young and middle-aged women in emergency medical care." Current scientific research in the modern world 10-7 (2019): 83-86. (in Russ).
Khasanjanova F.O. "The effect of thrombolytic therapy on the systolic function of the left ventricle in acute coronary syndrome with ST segment elevation at a young age." Current scientific research in the modern world 10-7 (2019): 91-95. (in Russ).
Khasanjanova, F. O., et al. "Evaluation of the effectiveness of thrombolytic therapy in men with acute coronary myocardial infarction in young age." Central Asian Journal of Medical and Natural Science 2.1 (2021): 144-149.
Khasanjanova, F. O., et al. "Features Influence of Risk Factors on Treatment Outcome in Young Patients with Acute Coronary Syndrome with St Segment Elevation." JournalNX: 222-226.
Khasanjanova, F. O., et al. "Peculiarities of recovery of myocardial stunnig zones in acute myocardial infarction under the influence of corvithin." EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE 3.5 (2023): 34-37.
Khasanjanova, Farida Odilovna. "Features of the clinical course and electrocardiogaphy data of coronary heart disease in men in young and elderly age." Евразийский журнал медицинских и естественных наук 2.5 (2022): 227-233.
Hajibeygi , R., Mirghazanfari , S. M., Pahlavani , N., Jalil, A. T., Alshahrani , S. H., Rizaev , J. A., ... & Yekta , N. H. (2022). Effect of a diet based on Iranian traditional medicine on inflammatory markers and clinical outcomes in COVID-19 patients: A double-blind, randomized, controlled trial. European Journal of Integrative Medicine, 102179.
Zeynitdinova , Z. A. , RIZAEV , J. A. , & Oripov , F. WITH . (2022). The degree of cytological damage to the epithelium of the buccal mucosa in COVID-19. JOURNAL OF BIOMEDICINE AND PRACTICE, 7(2).
Umirzakov Zokir , Rizaev Jasur , UMIROV Safar . The phenomenon of the epidemic
covid-19 process and their leading determinants. Journal of Biomedicine and Practice. 2021, vol . 6, issue 6, pp . 286-295
Статья поступила в редакцию 10.07.2024; одобрена после рецензирования 21.08.2024; принята к публикации 24.08.2024.
The article was submitted 10.07.2024; approved after reviewing 21.08.2024; accepted for publication 24.08.2024.
Информация об авторах:
Хасанжанова Фарида Одыловна – PhD кафедры внутренних болезней и кардиологии №2. Самаркандский государственный медицинский университет, Самарканд, Узбекистан. Е-mail:faridaxasanjanova070785@gmail.com https://orcid.org/0000-0001-7802-3307
Ёрбулов Лазиз Салим угли – стажер ассистент кафедры внутренних болезней и кардиологии №2. Самаркандский государственный медицинский университет, Самарканд, Узбекистан. Е-mail: sammi@sammi.uz, https://orcid.org/0000-0000-0000-0000
Источники финансирования: Работа не имела специального финансирования.
Конфликт интересов: Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Вклад авторов:
Хасанжанова Ф.О. — идеологическая концепция работы, редактирование статьи;
Ёрбулов Л.С. — сбор и анализ источников литературы.
Information about the authors:
Khasanjanova Farida Odylovna – PhD of the Department of Internal Medicine and Cardiology №2. Samarkand State Medical University, Samarkand, Uzbekistan. E-mail: faridaxasanjanova070785@gmail.com https://orcid.org/0000-0001-7802-3307
Yorbulov Laziz Salim ugli - is a trainee assistant at the Department of Internal Medicine and Cardiology No. 2. Samarkand State Medical University, Samarkand, Uzbekistan. E-mail: sammi@sammi.uz, https://orcid.org/0000-0000-0000-0000
Sources of funding: The work did not have special funding.
Conflict of interest: The authors declare the absence of obvious and potential conflicts of interest related to the publication of this article.
Contribution of the authors:
Khasanjanova F.O. — the ideological concept of the work, editing the article;
Yorbulov L.S. — collection and analysis of literature sources.
